Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    22356324 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib
2 Active, not recruiting
Has Results
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Condition: Malignant Melanoma
Intervention: Drug: vemurafenib

Indicates status has not been verified in more than two years